Literature DB >> 10398098

Widespread chromosomal abnormalities in high-grade ductal carcinoma in situ of the breast. Comparative genomic hybridization study of pure high-grade DCIS.

E Moore1, H Magee, J Coyne, T Gorey, P A Dervan.   

Abstract

For a variety of technical reasons it is rarely possible to study cytogenetic abnormalities in ductal carcinoma in situ (DCIS) using traditional techniques. However, by combining molecular biology and computerized image analysis it is possible to carry out cytogenetic analyses on formalin-fixed, paraffin-embedded tissue, using comparative genomic hybridization (CGH). The purpose of this study was to identify the prevalence of chromosomal amplifications and deletions in high-grade DCIS and to look specifically for unique or consistent abnormalities in this pre-invasive cancer. Twenty-three cases of asymptomatic, non-palpable, screen-detected, high-grade DCIS were examined using CGH on tumour cells obtained from histology slides. All cases showed chromosomal abnormalities. A wide variety of amplifications and deletions were spread across the genome. The most frequent changes were gains of chromosomes 17 (13 of 23), 16p (13 of 23), and 20q (9 of 23) and amplifications of 11q13 (22 of 23), 12q 24.1-24.2 (12 of 23), 6p21.3 (11 of 23), and 1q31-qter (6 of 23). The most frequent deletions were on 13q 21.3-q33 (7 of 23), 9p21 (4 of 23), and 6q16.1 (4 of 23). These findings indicate that high-grade DCIS is, from a cytogenetic viewpoint, an advanced lesion. There was no absolutely consistent finding in every case, but amplification of 11q13 was found in 22 of the 23 cases. The precise significance of this is unknown at present. This region of chromosome 11q harbours a number of known oncogenes, including cyclin D1 andINT2. It is likely that many of these findings are the result of accumulated chromosomal abnormalities, reflecting an unstable genome in established malignancy. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398098     DOI: 10.1002/(SICI)1096-9896(199903)187:4<403::AID-PATH284>3.0.CO;2-J

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  Genetic characterisation of invasive breast cancer: a comparison of CGH and PCR based multiplex microsatellite analysis.

Authors:  H Buerger; H Schmidt; A Beckmann; K S Zänker; W Boecker; B Brandt
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

Review 2.  Wip1 phosphatase in breast cancer.

Authors:  A Emelyanov; D V Bulavin
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

3.  Pro-tumorigenic effects of miR-31 loss in mesothelioma.

Authors:  Sergey V Ivanov; Chandra M V Goparaju; Peter Lopez; Jiri Zavadil; Ginat Toren-Haritan; Shai Rosenwald; Moshe Hoshen; Ayelet Chajut; Dalia Cohen; Harvey I Pass
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

4.  Large palpable ductal carcinoma in situ is Her-2 positive with high nuclear grade.

Authors:  Ahmad Monabati; Ali-Reza Sokouti; Sadat Noori Noori; Akbar Safaei; Abd-Rasul Talei; Shapoor Omidvari; Negar Azarpira
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

5.  Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer.

Authors:  O Monni; M Barlund; S Mousses; J Kononen; G Sauter; M Heiskanen; P Paavola; K Avela; Y Chen; M L Bittner; A Kallioniemi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

Review 6.  Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation?

Authors:  Alan K Meeker; Pedram Argani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-07       Impact factor: 2.673

7.  The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.

Authors:  Monica Cardone; Ayten Kandilci; Cintia Carella; Jonas A Nilsson; Jennifer A Brennan; Sema Sirma; Ugur Ozbek; Kelli Boyd; John L Cleveland; Gerard C Grosveld
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 8.  Telomeres, stem cells, senescence, and cancer.

Authors:  Norman E Sharpless; Ronald A DePinho
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

9.  The interrelationship between DRIM gene expression and cytogenetic and phenotypic characteristics in human breast tumor cell lines.

Authors:  Steve Goodison; Carrie Viars; Maren Grazzini; Virginia Urquidi
Journal:  BMC Genomics       Date:  2003-09-22       Impact factor: 3.969

Review 10.  The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions.

Authors:  Stefanie S Jeffrey; Jonathan R Pollack
Journal:  Breast Cancer Res       Date:  2003-10-09       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.